No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis

被引:0
|
作者
Blok, P
Craanen, ME
Dekker, W
Offerhaus, GJA
Tytgat, GNJ
机构
[1] Westeinde Ziekenhuis, Dept Pathol, NL-2501 CK The Hague, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Gastroenterol, NL-1066 CX Amsterdam, Netherlands
[4] Kennemer Gasthuis, Dept Internal Med, NL-2035 RC Haarlem, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands
来源
JOURNAL OF PATHOLOGY | 1998年 / 186卷 / 01期
关键词
early gastric cancer; p; 53; MDM2; carcinogenesis; immunohistochemistry;
D O I
10.1002/(SICI)1096-9896(199809)186:1<36::AID-PATH150>3.0.CO;2-R
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inactivation of wild-type p53 during gastric carcinogenesis is usually caused by mutations within exons 5-8 of the p53 gene leading to mutated, usually immunohistochemically detectable p53 proteins, However, functional inactivation of wild-type p53, mimicking mutational inactivation, may also result from binding to overexpressed MDM2 protein, While these two mechanisms of p53 inactivation are considered to be mutually exclusive, no data exist as to whether MDM2 overexpression occurs during gastric carcinogenesis. MDM2 protein overexpression was therefore studied in relation to p53 protein accumulation in gastric carcinogenesis. Forty-five paraffin-embedded gastrectomy specimens from early gastric carcinomas were examined for the presence of chronic active gastritis, chronic atrophic gastritis, subtypes of intestinal metaplasia, and dysplasia, The Lauren type was reassessed for all early carcinomas. p53 protein accumulation was examined using the monoclonal antibody DO-7. MDM2 protein overexpression was assessed with the monoclonal antibody SMP-14. Complete absence of nuclear p53 protein accumulation was observed in chronic active gastritis, chronic atrophic gastritis, and intestinal metaplasia, irrespective of the subtype, In gastric dysplasia (one mild, two moderate, one severe), only severe dysplasia was p53-positive, Intestinal-type (n=20) and diffuse-type early gastric carcinoma (n=25) were p53-positive in 70 and 52 per cent of the cases, respectively. MDM2 protein overexpression was not observed during gastric carcinogenesis, either in the p53-positive or in the p53-negative cases, In conclusion, it appears that functional inactivation of wild-type p53 by MDM2 protein overexpression plays no role in (early) gastric carcinogenesis. (C) 1998 John Wiley & Sons, Ltd.
引用
收藏
页码:36 / 40
页数:5
相关论文
共 50 条
  • [31] MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53
    Klein, Alyssa M.
    Biderman, Lynn
    Tong, David
    Alaghebandan, Bita
    Plumber, Sakina A.
    Mueller, Helen S.
    van Vlimmeren, Anne
    Katz, Chen
    Prives, Carol
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (44)
  • [32] Wild-type p53 overexpression: What role in tumorigenesis?
    Wolf, JK
    Wharton, JT
    GYNECOLOGIC ONCOLOGY, 1996, 60 (03) : 337 - 338
  • [33] MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel
    SHEN HongChang
    Science Bulletin, 2012, (09) : 1007 - 1012
  • [34] Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer
    Choi, Tae Gyu
    Minh Nam Nguyen
    Kim, Jieun
    Jo, Yong Hwa
    Jang, Miran
    Ngoc Ngo Yen Nguyen
    Yun, Hyeong Rok
    Choe, Wonchae
    Kang, Insug
    Ha, Joohun
    Tang, Dean G.
    Kim, Sung Soo
    JOURNAL OF PATHOLOGY, 2018, 246 (01): : 115 - 126
  • [35] Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53
    He, Tianli
    Guo, Jiayou
    Song, Hongmei
    Zhu, Hongcheng
    Di, Xiaoke
    Min, Hua
    Wang, Yuandong
    Chen, Guangzong
    Dai, Wangshu
    Ma, Jianhua
    Sun, Xinchen
    Ma, Jianxin
    PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (01) : 75 - 81
  • [36] High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines
    Ungar, S
    VandeMeeren, A
    Tammilehto, L
    Linnainmaa, K
    Mattson, K
    Gerwin, BI
    BRITISH JOURNAL OF CANCER, 1996, 74 (10) : 1534 - 1540
  • [37] MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel
    SHEN HongChangDONG WeiGAO DongWeiWANG GuangHuiMA GuoYuanLIU Qi DU JiaJun Department of Thoracic SurgeryProvincial Hospital Affiliated to Shandong UniversityShandong UniversityJinan China
    Chinese Science Bulletin, 2012, 57 (09) : 1007 - 1012
  • [38] MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel
    Shen HongChang
    Dong Wei
    Gao DongWei
    Wang GuangHui
    Ma GuoYuan
    Liu Qi
    Du JiaJun
    CHINESE SCIENCE BULLETIN, 2012, 57 (09): : 1007 - 1012
  • [39] COTRANSLATION OF ACTIVATED MUTANT P53 WITH WILD-TYPE DRIVES THE WILD-TYPE P53 PROTEIN INTO THE MUTANT CONFORMATION
    MILNER, J
    MEDCALF, EA
    CELL, 1991, 65 (05) : 765 - 774
  • [40] Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
    Mitobe, Yuta
    Suzuki, Shuhei
    Nakagawa-Saito, Yurika
    Togashi, Keita
    Sugai, Asuka
    Sonoda, Yukihiko
    Kitanaka, Chifumi
    Okada, Masashi
    CANCERS, 2023, 15 (17)